All individual trials at Idorsia Pharmaceuticals Ltd.
Trials reported
13 out of 13
Percent reported
100.0%
US Govt could have imposed fines of at least
$1,712,212
Fines claimed by US Govt
$0
Showing 1 to 20 of 20 entries
Status | Sponsor | Trial ID | Title | Completion date | Days overdue |
---|---|---|---|---|---|
reported | Idorsia Pharmaceuticals Ltd. | NCT02472795 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-response Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus [pACT] | 2017-01-23 | |
reported | Idorsia Pharmaceuticals Ltd. | NCT02603809 | A Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2, Dose-finding Study With ACT-132577 in Subjects With Essential Hypertension (Grade 1 and 2). [pACT] | 2017-02-28 | |
reported | Idorsia Pharmaceuticals Ltd. | NCT02839200 | Multi-center, Double-blind, Randomized, Placebo-controlled, Active-reference, Parallel-group, Polysomnography Dose-response Study to Assess the Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder [pACT] | 2017-04-12 | |
reported | Idorsia Pharmaceuticals Ltd. | NCT02841709 | Multi-center, Double-blind, Randomized, Placebo-controlled, 5-period, 5-treatment Crossover, Polysomnography Dose-response Study to Assess the Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder [pACT] | 2017-05-31 | |
reported | Idorsia Pharmaceuticals Ltd. | NCT03384966 | A Multi-center, Double-blind, Randomized, Placebo-controlled Study to Assess the Pharmacodynamics, Pharmacokinetics, Tolerability, and Safety of a Single Subcutaneous Injection of ACT-246475 in Adults With Stable Coronary Artery Disease | 2018-08-18 | |
reported | Idorsia Pharmaceuticals Ltd. | NCT03487445 | A Multi-center, Open-label, Randomized, Study to Assess the Onset of Platelet Aggregation Inhibition After a Single Subcutaneous Injection of ACT-246475 in Adults With Acute Myocardial Infarction | 2018-11-10 | |
reported | Idorsia Pharmaceuticals Ltd. | NCT03545191 | Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography Study to Assess the Efficacy and Safety of ACT-541468 in Adult and Elderly Subjects With Insomnia Disorder | 2020-01-25 | |
reported | Idorsia Pharmaceuticals Ltd. | NCT03575104 | Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography Study to Assess the Efficacy and Safety of ACT-541468 in Adult and Elderly Subjects With Insomnia Disorder | 2020-04-09 | |
reported | Idorsia Pharmaceuticals Ltd. | NCT03679884 | Multi-center, Double-blind, Parallel-group, Randomized, Placebo-controlled, Three Doses, 40-week Extension to Studies ID-078A301 and ID-078A302 to Assess the Long Term Safety and Tolerability of ACT-541468 in Adult and Elderly Subjects With Insomnia Disorder | 2021-02-22 | |
reported-late | Idorsia Pharmaceuticals Ltd. | NCT03541174 | Multi-center, Blinded, Randomized, Parallel-group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension (RHT) | 2021-05-14 | 178 |
ongoing | Idorsia Pharmaceuticals Ltd. | NCT03425539 | A Multicenter, dOuble-blind, ranDomized, Placebo-controlled, Parallel-group Study to Determine the effIcacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With FabrY Disease | 2021-08-17 | |
reported | Idorsia Pharmaceuticals Ltd. | NCT03742037 | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Subjects With Moderate to Severe Systemic Lupus Erythematosus (SLE) | 2021-08-31 | |
reported | Idorsia Pharmaceuticals Ltd. | NCT04753164 | Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Proof-of-concept Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder | 2022-03-21 | |
reported | Idorsia Pharmaceuticals Ltd. | NCT03585270 | A Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Assess the Efficacy and Safety of Clazosentan in Preventing Clinical Deterioration Due to Delayed Cerebral Ischemia (DCI), in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage (aSAH) | 2022-06-13 | |
ongoing | Idorsia Pharmaceuticals Ltd. | NCT05597020 | A Multi-center, Double-blind, Randomized, Placebo-controlled, 2-way Cross-over Post Approval Study to Investigate the Efficacy of Daridorexant in Subjects With Insomnia and Comorbid Nocturia | 2024-04-25 | |
ongoing | Idorsia Pharmaceuticals Ltd. | NCT05423717 | Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography, Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-dose Oral Administration of Daridorexant in Pediatric Subjects Aged 10 to < 18 Years With Insomnia Disorder | 2025-03-06 | |
ongoing | Idorsia Pharmaceuticals Ltd. | NCT04957719 | Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Self-administered Subcutaneous Selatogrel for Prevention of All-cause Death and Treatment of Acute Myocardial Infarction in Subjects With a Recent History of Acute Myocardial Infarction | 2025-08-31 | |
ongoing | Idorsia Pharmaceuticals Ltd. | NCT03737214 | A Multi-center, Open-label, Uncontrolled, Single-arm, Extension Study to Determine the Long-term Safety and Tolerability of Oral Lucerastat in Adult Subjects With Fabry Disease | 2025-10-29 | |
ongoing | Idorsia Pharmaceuticals Ltd. | NCT05648500 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Adult Subjects With Moderate-to-Severe Systemic Lupus Erythematosus (SLE) on Top of Background Therapy | 2025-12-31 | |
ongoing | Idorsia Pharmaceuticals Ltd. | NCT05672576 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Adult Subjects With Moderate-to-severe Systemic Lupus Erythematosus (SLE) on Top of Background Therapy | 2026-01-31 |